Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Actinomycetales Infections

ClinicalTrials.gov lists 1,974 trials for Actinomycetales Infections or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 116.

MeSH D000193 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 212 Phase 1/2 Phase 1/2 38 Phase 2 Phase 2 279 Phase 2/3 Phase 2/3 46 Phase 3 Phase 3 266 Phase 4 Phase 4 164 Not applicable Not applicable 429 Observational Observational 538 Phase 1 Phase 1 212 Phase 1/2 Phase 1/2 38 Phase 2 Phase 2 279 Phase 2/3 Phase 2/3 46 Phase 3 Phase 3 266 Phase 4 Phase 4 164 Not applicable Not applicable 429 Observational Observational 538

Trials per phase

1 more section with rows

2 of the 1,974 trials are tagged with Actinomycetales Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Actinomycetales Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Actinomycetales Infections trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 117

1990: 1 trials (Phase 2 1) 1991: 2 trials (Phase 4 1, Phase 2 1) 1992: 2 trials (Observational 1, Phase 2 1) 1994: 6 trials (Observational 1, Not applicable 1, Phase 4 3, Phase 2 1) 1995: 10 trials (Observational 7, Not applicable 1, Phase 3 1, Phase 1 1) 1996: 1 trials (Phase 4 1) 1997: 2 trials (Not applicable 1, Phase 3 1) 1998: 4 trials (Phase 3 1, Phase 2 2, Phase 1 1) 1999: 7 trials (Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 1) 2000: 10 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 4, Phase 2 1) 2001: 8 trials (Observational 1, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 1) 2002: 15 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 3 5, Phase 2 3, Phase 1 1) 2003: 26 trials (Observational 4, Not applicable 3, Phase 4 6, Phase 3 7, Phase 2 3, Phase 1 3) 2004: 31 trials (Observational 6, Not applicable 3, Phase 4 6, Phase 3 7, Phase 2/3 2, Phase 2 3, Phase 1/2 1, Phase 1 3) 2005: 52 trials (Observational 17, Not applicable 5, Phase 4 5, Phase 3 13, Phase 2 7, Phase 1 5) 2006: 72 trials (Observational 14, Not applicable 4, Phase 4 8, Phase 3 29, Phase 2/3 2, Phase 2 9, Phase 1/2 2, Phase 1 4) 2007: 61 trials (Observational 15, Not applicable 8, Phase 4 8, Phase 3 17, Phase 2/3 1, Phase 2 2, Phase 1 10) 2008: 71 trials (Observational 12, Not applicable 8, Phase 4 13, Phase 3 14, Phase 2 11, Phase 1 13) 2009: 79 trials (Observational 20, Not applicable 19, Phase 4 6, Phase 3 9, Phase 2/3 1, Phase 2 12, Phase 1/2 1, Phase 1 11) 2010: 86 trials (Observational 21, Not applicable 6, Phase 4 12, Phase 3 11, Phase 2/3 1, Phase 2 20, Phase 1/2 2, Phase 1 13) 2011: 75 trials (Observational 16, Not applicable 11, Phase 4 12, Phase 3 16, Phase 2 13, Phase 1 7) 2012: 79 trials (Observational 26, Not applicable 14, Phase 4 9, Phase 3 8, Phase 2/3 2, Phase 2 9, Phase 1/2 1, Phase 1 10) 2013: 69 trials (Observational 14, Not applicable 14, Phase 4 5, Phase 3 9, Phase 2/3 2, Phase 2 11, Phase 1/2 4, Phase 1 10) 2014: 73 trials (Observational 16, Not applicable 17, Phase 4 7, Phase 3 13, Phase 2/3 3, Phase 2 12, Phase 1/2 2, Phase 1 3) 2015: 83 trials (Observational 23, Not applicable 22, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 12) 2016: 77 trials (Observational 21, Not applicable 16, Phase 4 7, Phase 3 9, Phase 2/3 1, Phase 2 12, Phase 1/2 1, Phase 1 10) 2017: 84 trials (Observational 26, Not applicable 20, Phase 4 5, Phase 3 6, Phase 2/3 2, Phase 2 9, Phase 1/2 3, Phase 1 13) 2018: 71 trials (Observational 24, Not applicable 22, Phase 4 2, Phase 3 2, Phase 2/3 3, Phase 2 7, Phase 1/2 2, Phase 1 9) 2019: 117 trials (Observational 41, Not applicable 29, Phase 4 3, Phase 3 9, Phase 2/3 4, Phase 2 17, Phase 1/2 5, Phase 1 9) 2020: 85 trials (Observational 22, Not applicable 24, Phase 4 6, Phase 3 7, Phase 2/3 5, Phase 2 11, Phase 1 10) 2021: 111 trials (Observational 39, Not applicable 33, Phase 4 8, Phase 3 6, Phase 2/3 2, Phase 2 17, Phase 1 6) 2022: 95 trials (Observational 31, Not applicable 22, Phase 4 7, Phase 3 9, Phase 2/3 4, Phase 2 14, Phase 1/2 2, Phase 1 6) 2023: 92 trials (Observational 27, Not applicable 24, Phase 4 4, Phase 3 7, Phase 2/3 3, Phase 2 14, Phase 1/2 2, Phase 1 11) 2024: 96 trials (Observational 37, Not applicable 24, Phase 4 6, Phase 3 9, Phase 2/3 1, Phase 2 8, Phase 1/2 4, Phase 1 7) 2025: 73 trials (Observational 23, Not applicable 18, Phase 4 2, Phase 3 9, Phase 2/3 3, Phase 2 10, Phase 1 8)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 95
2025 73
2024 96
2023 92
2022 95
2021 111
2020 85
2019 117
2018 71
2017 84

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 110 trials starting in 2026 and about 86 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 134 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 1,244 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Actinomycetales Infections trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 212
Phase 1/2 38
Phase 2 279
Phase 2/3 46
Phase 3 266
Phase 4 164
Not applicable 429
Observational 538
Expanded access 2

How many Actinomycetales Infections trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 86
Recruiting 163
Enrolling by invitation 14
Active, not recruiting 53
Completed 1,256

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Actinomycetales Infections trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 116
National Institute of Allergy and Infectious Diseases (NIAID) 113
Sanofi Pasteur, a Sanofi Company 58
Centers for Disease Control and Prevention 29
Sanofi 20

Which drugs are being tested for Actinomycetales Infections? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Bedaquiline 61
Rifabutin 33
Clofazimine 28
Delamanid 26
MVA85A 22

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Isoniazida 104
Rifampicin 88
Pyrazinamide Oral Product 60
Ethambutol Oral Product 57
C: moxifloxacin 45

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Actinomycetales Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Gastroenteritis 495 61
Pneumonia 394 82
Death 378 25
Bronchiolitis 335 30
Bronchopneumonia 130 31

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Actinomycetales Infections? (2)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Tropheryma whipplei colonization in HIV-infected individuals is not associated with lung function or inflammation. PloS one 2018 Yes
The clinical importance of microbiological findings in the diagnosis and management of bloodstream infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009 No

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages